

ASX ANNOUNCEMENT

**4TH MIDKINE SYMPOSIUM TO BE HELD IN BUDAPEST
28-30 APRIL 2016**

- **Hosted by the Hungarian Institute of Foreign Affairs and Trade and Pharmahungary**
- **Interviews by PharmaTelevision® broadcast to a wide biopharma audience**
- **Key opinion leaders from eleven countries presenting on midkine research**

SYDNEY, 4 April 2016: Cellmid Limited (ASX: CDY) will be holding the 4th Midkine Symposium between 28th and 30th April 2016 in Budapest, Hungary. The Symposium will be a global meeting of key opinion leaders, clinicians and scientists involved in midkine (MK) research. This is a scientific meeting of experts from eleven countries representing a number of therapeutic and diagnostic fields.

The event follows on the success of the previous three scientific meetings on MK held in Sydney, Istanbul and Kyoto. Previous meetings resulted in a number of collaborations, including the most recent preclinical agreement with Complutense University in Madrid, where researchers are currently assessing Cellmid's MK antibodies in a glioblastoma model in conjunction with cannabinoid treatment, amongst other studies.

In a major endorsement of the event the Symposium will be hosted by Cellmid partner Pharmahungary and the Hungarian Institute of Foreign Affairs and Trade, the leading government organisation responsible for international trade policy development. Director-General of the Institute, Marton Schoberl, will be welcoming Symposium delegates.

Significantly, PharmaTelevision® will be attending the Symposium this year. They will record and broadcast interviews with key delegates on MK research and on commercialisation of medical innovation. PharmaTelevision®, based in Oxford UK, has been the leading online news channel for the biopharma industry since 2006.

With a global audience of 18,000+, including senior industry executives, PharmaTelevision® channels include *News Review* featuring interviews with experts. Interviews recorded during the Symposium will be made available to shareholders on the Cellmid website following the meeting.

The Symposium agenda includes presentations on unpublished and patentable research, and for this reason the meeting itself and the lectures on the agenda will not be recorded. Amongst the 22 presenters Symposium Patrons, Emeritus Professor Takashi Muramatsu and Professor Kenji Kadomatsu, will be outlining the progress made in midkine research since the last conference in 2014. Further details of the meeting are available on the Cellmid website, www.cellmid.com.au/content_common/pg-midkine-conference.seo.

"It is promising to be the most productive Midkine Symposium yet accelerating the progress of our therapeutic and diagnostic programs" said Symposium Chair and Head of Research and Development at Cellmid, Associate Professor Graham Robertson.

End
Contact:
Maria Halasz, CEO
T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programmes in multiple disease indications. The Company is developing innovative novel therapies and diagnostic tests for cancer and inflammatory diseases. Through its wholly owned subsidiaries, Advangen Limited and Advangen Inc., Cellmid also develops and sells FGF5 inhibitor hair loss products. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au and www.evolisproducts.com.au.

Advangen Limited and hair growth products

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, China and Taiwan. Concurrently, Advangen has been developing midkine, a growth factor, for hair loss utilising its anti-apoptotic effects. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is highly anti-apoptotic protecting cells from dying. It is this mechanism of action that is thought to be responsible for midkine's ability to regenerate hair growth in various models of the condition.